0.68
-0.1105(-14.07%)
Currency In USD
| Previous Close | 0.79 |
| Open | 0.7 |
| Day High | 0.75 |
| Day Low | 0.65 |
| 52-Week High | 737.5 |
| 52-Week Low | 0.36 |
| Volume | 2.08M |
| Average Volume | 5.39M |
| Market Cap | 2.44M |
| PE | 0 |
| EPS | -6,321.5 |
| Moving Average 50 Days | 0.75 |
| Moving Average 200 Days | 18.2 |
| Change | -0.11 |
If you invested $1000 in Windtree Therapeutics, Inc. (WINT) 10 years ago, it would be worth $0 as of July 10, 2025 at a share price of $0.675. Whereas If you bought $1000 worth of Windtree Therapeutics, Inc. (WINT) shares 5 years ago, it would be worth $0.04 as of July 10, 2025 at a share price of $0.675.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure
GlobeNewswire Inc.
Jul 02, 2025 1:00 PM GMT
1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old If istaroxime is approved in the US for acute heart failure, this patent would provide protection
Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis
GlobeNewswire Inc.
Jun 30, 2025 1:00 PM GMT
The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously reported two positive early cardiogenic shock Pha
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
GlobeNewswire Inc.
Jun 26, 2025 8:05 PM GMT
Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026 Tech transfer underway with validation batch manu